Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2099-2105

  Den Otter, Willem ^a   Van Moorselaar, R Jeroen ^a   Jacobs, John J L ^a   Ter Haar, Ronald ^a   Koten, Jan W ^a   Dobrowolski, Zygmunt ^b   Lipczynski, Waclaw ^b   Pašukoniene, Vita ^c   Characiejus, Dainius ^c   Jankevičius, Feliksas ^c   Eidukevičius, Rimantas ^c   De Reijke, Theo M ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c VILNIUS UNIVERSITY   (Lithuania)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

IL 2; Interleukin 2; Marker tumour; NMIBC; Non muscle invasive bladder carcinoma

Indexed keywords

INTERLEUKIN 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THERAPY EFFECT; TRANSURETHRAL RESECTION; TREATMENT DURATION; TUMOR VOLUME;

IL-2; INTERLEUKIN-2; MARKER TUMOUR; NMIBC; NON-MUSCLE INVASIVE BLADDER CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; LITHUANIA; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; POLAND; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84878207423     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brausi M, Collette L, Kurth K, Van der Meijden APM, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ, EORTC Genito-Urinary Tract Cancer Collaborative Group: Variability in the recurrence rate at first follow-up cytoscopy after TUR in stage Ta-T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol 41: 523-531, 2002.
2. Sylvester RJ, Van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-477, 2006.
3. Lamm DL, Van der Meijden APM, Akaza H, Brendler C, Hedlund PO, Mizutani Y, Ratliff TL, Robinson MR and Shinka T : Intravesical chemo- and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Proceedings of the Fourth International Bladder Cancer Consensus Conference. Int J Urol 2(S2): 23-35, 1995.
4. Van der Meijden APM, Hall RR, Kurth KH, Bouffioux C, Sylvester R : Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Br J Urol 77: 634-637, 1996.
5. Van der Meijden APM: The use of the marker tumor concept in TaT1 bladder cancer: Is it justified? Urol Oncol 7: 31-33, 2002.
6. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM and Koten JW: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950, 2008.
7. Jacobs JJL, Characiejus D, Tomova R, Baran J, Bubenik J, Zembala M, Krastev Z, Scheper RJ, Pawelec G and Den Otter W: Local rather than systemic immunotherapy has therapeutic efficacy against metastasized cancer. Trends in Cancer Research 7: 1-14, 2011.
8. Van Es RJ, Baselmans AH, Koten JW, Van Dijk JE, Koole R and Den Otter W Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic antitumour activity. Anticancer Res 20: 4163-4170, 2000.
9. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rutten VP and Ruitenberg EJ: Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13: 2453-2455, 1993. (Pubitemid 24103291)
10. Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW and Den Otter W: Treatment of ocular squamous cell carcinomas in cattle using interleukin-2. Vet Rec 159: 668-672, 2006. (Pubitemid 44823366)
11. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden AP, Koten JW, Boon TA, Siedlar M and Zembala M: Intravesical Interleukin-2 in T1 bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 159: 1183-1186, 1998. (Pubitemid 28172790)
12. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ and Den Otter W: Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54: 792-798, 2005. (Pubitemid 40977147)
13. Magno C, Melloni D, Gali A, Mucciardi G, Nicocia G, Morandi B, Melioli G and Ferlazzo G: The antitumor activity of bacillus Calmette-Guerin in bladder carcinoma is associated with an increase in the circulating level of interleukin-2. Immunol Lett 81: 235-238, 2002. (Pubitemid 34310231)
14. Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S, OhmotoY and Naito K: Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52: 481-486, 2003.
15. De Reijke TM, De Boer EC, Kurth KH and Schamhart DH: Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: Can it predict the optimal number of instillations? J Urol 161: 67-71, 1999. (Pubitemid 29422293)
16. Characiejus D, Pašukonienė V, Jacobs JJL, Eidukevičius R,Jankevičius F, Dobrovolskienė N, Mauricas M, Van MoorselaarRJA and Den Otter W: Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res 31: 699-703, 2011.
17. Jacobs JJL, Characiejus D, Pašukonienė V, Jankevičius F, VanMoorselaar RJA, Mauricas M and Den Otter W: Recurrences of superficial bladder carcinoma are associated with a raise of CD8highCD57+ and CD8low T lymphocytes in peripheral blood. Open Cancer Immunol J 3: 8-14, 2010.
18. Pizza G, Severini G, Menniti D, De Vinci C and Corrado F: Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34: 359-367, 1984. (Pubitemid 14032186)
19. Huland E and Huland H: Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469-5474, 1989. (Pubitemid 19240491)
20. Gomella LG, McGinnis DE, Lattime EC, Butler K, Baltish M, Thompson I and Marshall ME: Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: A pilot study. Cancer Biother 8: 223-227, 1993. (Pubitemid 23321989)
21. Ferlazzo G, Magno C, Iemmo R, Rizzo M, Lupo G, Semino C, Bruno S and Melioli G: Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: A follow-up study. Anticancer Res 16: 979-980, 1996. (Pubitemid 26182043)
22. Tubaro A, Vicentini C, Bossola PC, Galassi P, Miano L, Velotti F, Santoni A, Pettinato A, Morrone S, Napolitano T, Frati L, Stoppacciaro A, Ruco L, Franks CR, Palmer PA and Pourreau CN: Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study. Cancer 68: 56-61, 1991.
23. Velotti F, Piccoli M, Frati L, Franks CR, Palmer P, Pourreau CN and Santoni A: Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study. Ann Ist Super Sanita 26: 411-421, 1990.
24. Grasso M, Torelli F, Scannapieco G, Franzoso F and Lania C: Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 24: 184-187, 2001. (Pubitemid 32183064)
25. Sadoun D, Rosenzwaig M, Jily F, Six A, Carrat F, Thibault V, Sene D, Cacoub P and Klatzman D: Regulatory T-cell responses to low-dose interleukin-2 in HCV induced vasculitis. N Engl J Med 365: 2067-2077, 2011.
26. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J and Soiffer RJ: Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365: 2055-2066, 2011.
27. Tomova R, Pomakov J, Jacobs JJL, Adjarov D, Popova S, Altankova I, Den Otter W and Krastev Z: Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res 26: 2037-2047, 2006. (Pubitemid 43989467)